These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Schaller G; Scheiber-Mojdehkar B; Wolzt M; Puttinger H; Mittermayer F; Hörl WH; Födinger M; Sunder-Plassmann G; Vychytil A Kidney Int; 2005 Dec; 68(6):2814-22. PubMed ID: 16316358 [TBL] [Abstract][Full Text] [Related]
3. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients. Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355 [TBL] [Abstract][Full Text] [Related]
4. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Aronoff GR; Bennett WM; Blumenthal S; Charytan C; Pennell JP; Reed J; Rothstein M; Strom J; Wolfe A; Van Wyck D; Yee J; Kidney Int; 2004 Sep; 66(3):1193-8. PubMed ID: 15327417 [TBL] [Abstract][Full Text] [Related]
5. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Ichii H; Masuda Y; Hassanzadeh T; Saffarian M; Gollapudi S; Vaziri ND Am J Nephrol; 2012; 36(1):50-7. PubMed ID: 22722756 [TBL] [Abstract][Full Text] [Related]
6. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB; Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248 [TBL] [Abstract][Full Text] [Related]
7. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). St Peter WL; Obrador GT; Roberts TL; Collins AJ Am J Kidney Dis; 2005 Oct; 46(4):650-60. PubMed ID: 16183420 [TBL] [Abstract][Full Text] [Related]
8. The efficiency of fractionated parenteral iron treatment in CAPD patients. Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661 [TBL] [Abstract][Full Text] [Related]
9. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H; Wang SX Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498 [TBL] [Abstract][Full Text] [Related]
10. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Weiss G; Meusburger E; Radacher G; Garimorth K; Neyer U; Mayer G Kidney Int; 2003 Aug; 64(2):572-8. PubMed ID: 12846752 [TBL] [Abstract][Full Text] [Related]
11. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. Krafft A; Breymann C J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035 [TBL] [Abstract][Full Text] [Related]
12. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Toblli JE; Lombraña A; Duarte P; Di Gennaro F J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Goldstein SL; Morris D; Warady BA Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582 [TBL] [Abstract][Full Text] [Related]
14. Intravenous iron supplementation in children on hemodialysis. Leijn E; Monnens LA; Cornelissen EA J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964 [TBL] [Abstract][Full Text] [Related]
15. Combination of intravenous iron sucrose and ascorbic acid in hemodialysis patients. Keven K; Kutlay S; Nergizoglu G; Erturk S Kidney Int; 2005 Jul; 68(1):411. PubMed ID: 15954940 [No Abstract] [Full Text] [Related]
16. Influence of recombinant human erythropoietin on neutrophil function in premature neonates. Soubasi V; Roilides E; Tsantali C; Mussafiris K; Tsakiris D; Kremenopoulos G Cytokine; 1999 Jan; 11(1):61-5. PubMed ID: 10080880 [TBL] [Abstract][Full Text] [Related]
17. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241 [TBL] [Abstract][Full Text] [Related]
18. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. Anbu AT; Kemp T; O'donnell K; Smith PA; Bradbury MG Acta Paediatr; 2005 Dec; 94(12):1738-41. PubMed ID: 16431410 [TBL] [Abstract][Full Text] [Related]
19. Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients. Hodkova M; Dusilova-Sulkova S; Skalicka A; Kalousova M; Zima T; Bartunkova J Ren Fail; 2005; 27(2):135-41. PubMed ID: 15807176 [TBL] [Abstract][Full Text] [Related]
20. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Cladellas M; Farré N; Comín-Colet J; Gómez M; Meroño O; Bosch MA; Vila J; Molera R; Segovia A; Bruguera J Am J Cardiol; 2012 Oct; 110(7):1021-6. PubMed ID: 22771376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]